GAITHERSBURG, Md., June 1, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the Jefferies Global Healthcare Conference.
Conference Details: |
||||||
Fireside Chat |
||||||
Date: |
Thursday, June 8, 2023 |
|||||
Time: |
9:00 – 9:25 a.m. Eastern Daylight Time (EDT) |
|||||
Location: |
New York, NY |
|||||
Moderator: |
Roger Song, M.D., CFA, Equity Research Analyst – Biotechnology |
|||||
Novavax participants: |
John C. Jacobs, President and Chief Executive Officer and Filip Dubovsky, M.D., President, Research and Development |
|||||
Conference |
||||||
Event: |
Investor Meetings |
|||||
Date: |
Thursday, June 8, 2023 |
|||||
Recordings
A replay of the recorded fireside session will be available through the Events and Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID, influenza, and COVID and influenza combined. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
[email protected]
Media
Ali Chartan
240-709-5563
[email protected]
SOURCE Novavax, Inc.
![](https://rt.prnewswire.com/rt.gif?NewsItemId=PH16389&Transmission_Id=202306011602PR_NEWS_USPR_____PH16389&DateId=20230601)
Share this article